379 related articles for article (PubMed ID: 21952281)
1. Evaluation of current cancer immunotherapy: hemato-oncology.
Hourigan CS; Levitsky HI
Cancer J; 2011; 17(5):309-24. PubMed ID: 21952281
[TBL] [Abstract][Full Text] [Related]
2. Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.
Braun DA; Wu CJ
Cancer J; 2017; 23(2):115-124. PubMed ID: 28410299
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of hematological malignancies using dendritic cells.
Van de Velde AL; Berneman ZN; Van Tendeloo VF
Bull Cancer; 2008 Mar; 95(3):320-6. PubMed ID: 18390412
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic system-specific antigens as targets for cellular immunotherapy of hematological malignancies.
Mutis T; Goulmy E
Semin Hematol; 2002 Jan; 39(1):23-31. PubMed ID: 11799526
[TBL] [Abstract][Full Text] [Related]
5. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches.
Noh JY; Seo H; Lee J; Jung H
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33121189
[TBL] [Abstract][Full Text] [Related]
7. Anti-cancer vaccine therapy for hematologic malignancies: An evolving era.
Nahas MR; Rosenblatt J; Lazarus HM; Avigan D
Blood Rev; 2018 Jul; 32(4):312-325. PubMed ID: 29475779
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell-based immunotherapy for the treatment of hematological malignancies.
Büchler T; Michalek J; Kovarova L; Musilova R; Hajek R
Hematology; 2003 Apr; 8(2):97-104. PubMed ID: 12745659
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers for checkpoint inhibition in hematologic malignancies.
Atanackovic D; Luetkens T
Semin Cancer Biol; 2018 Oct; 52(Pt 2):198-206. PubMed ID: 29775689
[TBL] [Abstract][Full Text] [Related]
10. Cancer vaccines for hematologic malignancies.
Borrello IM; Sotomayor EM
Cancer Control; 2002; 9(2):138-51. PubMed ID: 11965234
[TBL] [Abstract][Full Text] [Related]
11. The immune system as a foundation for immunologic therapy and hematologic malignancies: a historical perspective.
Baron F; Storb R
Best Pract Res Clin Haematol; 2006; 19(4):637-53. PubMed ID: 16997174
[TBL] [Abstract][Full Text] [Related]
12. [Cellular immunotherapy for hematological malignancies].
Yasukawa M
Rinsho Ketsueki; 2008 Oct; 49(10):1460-71. PubMed ID: 18833930
[No Abstract] [Full Text] [Related]
13. Cancer vaccines.
Rousseau RF; Hirschmann-Jax C; Takahashi S; Brenner MK
Hematol Oncol Clin North Am; 2001 Aug; 15(4):741-73. PubMed ID: 11676282
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapeutic approaches for hematologic malignancies.
Caligiuri MA; Velardi A; Scheinberg DA; Borrello IM
Hematology Am Soc Hematol Educ Program; 2004; ():337-53. PubMed ID: 15561691
[TBL] [Abstract][Full Text] [Related]
15. Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy.
Goulmy E
Cancer J; 2004; 10(1):1-7. PubMed ID: 15000488
[TBL] [Abstract][Full Text] [Related]
16. Translational development of active immunotherapy for hematologic malignancies.
Kwak LW
Int J Hematol; 2002 Aug; 76 Suppl 1():320-1. PubMed ID: 12430873
[TBL] [Abstract][Full Text] [Related]
17. Challenges in vaccine therapy in hematological malignancies and strategies to overcome them.
Nahas MR; Avigan D
Expert Opin Biol Ther; 2016 Sep; 16(9):1093-104. PubMed ID: 27220455
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies.
El-Khazragy N; Ghozy S; Emad P; Mourad M; Razza D; Farouk YK; Mohamed NA; Ahmed MK; Youssef T; Bahnasawy YM; Elmasery S
Immunotherapy; 2020 Dec; 12(18):1341-1357. PubMed ID: 33148070
[TBL] [Abstract][Full Text] [Related]
19. Immunobiology of haematological malignant disorders: the basis for novel immunotherapy protocols.
Costello RT; Fauriat C; Rey J; Gastaut JA; Olive D
Lancet Oncol; 2004 Jan; 5(1):47-55. PubMed ID: 14700608
[TBL] [Abstract][Full Text] [Related]
20. Is Disease-Specific Immunotherapy a Potential Reality for MDS?
Sallman DA; Davila ML
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S26-S30. PubMed ID: 28760299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
